What is the latest post-medical insurance cost of dacomitinib in 2024?

Dacomitinib (Dacomitinib), as an innovative oral second-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor (TKI), has demonstrated its unique efficacy in the treatment of non-small cell lung cancer (NSCLC). EGFR, a key cell signaling molecule, whose mutations play a central role in driving the occurrence and development of cancer in many NSCLC patients. Dacomitinib (Dacomitinib) uses its unique irreversible inhibition mechanism to precisely target EGFR and its common mutations, effectively preventing the proliferation and survival of tumor cells.

The good news for the majority of patients is that Dacomitinib is now available in China and has been successfully included in the medical insurance catalog, allowing patients to purchase it conveniently in China. Its specifications are 15 mg and 30 pills, and the price is close to the people, about more than one thousand yuan. For specific price information and relevant policies on medical insurance reimbursement, it is recommended that patients go to the pharmacy of the local hospital for detailed consultation to obtain the latest and most accurate information. In comparison, the price of Pfizer's original drug in the European market is relatively expensive, reaching more than 20,000 yuan. In the foreign market, the price is relatively more affordable for the generic drugs produced in Laos. Its specification is 45mg30 tablets. The price is only about a few thousand yuan, three times lower than the domestic price, and its drug ingredients are basically the same as the original drugs, providing patients with more choices.

Dacomitinib is unique in that it irreversibly binds to and inhibits the kinase activity of EGFR, not only against common EGFR mutations such as L858R and Exon 19Deletion has a significant effect and can also suppress some rare mutation types. This irreversible combination makes the drug more durable and more effective in inhibiting the growth of tumor cells. In 2018, the U.S. Food and Drug Administration (FDA) approved dacomitinib (dacomitinib) for the treatment of patients with metastatic non-small cell lung cancer with EGFR mutations. This landmark approval marks the widespread recognition of the clinical importance of this drug.